Nearly 50% of patients with psoriatic arthritis report elevated levels of fatigue.
The biosimilar has also been approved for Crohn's disease, ulcerative colitis, and ankylosing spondylitis.
Researchers found that the annual incidence rate of PsA was 2.7 cases per 100 psoriasis patients.
Apremilast was generally well tolerated among participants in the long-term PALACE 1 study.
Combination use of methotrexate and golimumab may significantly improve psoriatic arthritis symptomsNovember 11, 2015
Using methotrexate and golimumab in combination may significantly improve some symptoms among patients diagnoes with psoriatic arthritis.